173 related articles for article (PubMed ID: 31985841)
1. Combination of BRAF and MEK inhibition in BRAF V600E mutant low-grade ganglioglioma.
Yau WH; Ameratunga M
J Clin Pharm Ther; 2020 Oct; 45(5):1172-1174. PubMed ID: 31985841
[TBL] [Abstract][Full Text] [Related]
2. Response to the BRAF/MEK inhibitors dabrafenib/trametinib in an adolescent with a BRAF V600E mutated anaplastic ganglioglioma intolerant to vemurafenib.
Marks AM; Bindra RS; DiLuna ML; Huttner A; Jairam V; Kahle KT; Kieran MW
Pediatr Blood Cancer; 2018 May; 65(5):e26969. PubMed ID: 29380516
[TBL] [Abstract][Full Text] [Related]
3. Vemurafenib and cobimetinib overcome resistance to vemurafenib in
Touat M; Gratieux J; Condette Auliac S; Sejean K; Aldea S; Savatovsky J; Perkins G; Blons H; Ligon KL; Idbaih A; Hollebecque A; Gimenez-Roqueplo AP; Laurent-Puig P; Sanson M; Villa C; Di Stefano AL
Neurology; 2018 Sep; 91(11):523-525. PubMed ID: 30120137
[No Abstract] [Full Text] [Related]
4. Sustained Tumor Control With MAPK Inhibition in
Berzero G; Bellu L; Baldini C; Ducray F; Guyon D; Eoli M; Silvani A; Dehais C; Idbaih A; Younan N; Nguyen-Them L; Gaillard S; Pasqualetti F; Lepage-Seydoux C; Sekkate S; Tresca P; Kas A; Gratieux J; Ammari S; Saragoussi E; Savatovsky J; Delattre JY; Hoang-Xuan K; Meyronet D; Villa C; Bielle F; Sanson M; Touat M; Di Stefano AL
Neurology; 2021 Aug; 97(7):e673-e683. PubMed ID: 34088874
[TBL] [Abstract][Full Text] [Related]
5. Comment on: Response to the BRAF/MEK inhibitors dabrafenib/trametinib in an adolescent with a BRAF V600E mutated anaplastic ganglioglioma intolerant to vemurafenib.
Bourque MS; Salek M; Sabin ND; Canale M; Upadhyaya SA
Pediatr Blood Cancer; 2021 Apr; 68(4):e28814. PubMed ID: 33211390
[No Abstract] [Full Text] [Related]
6. Efficacy of Dabrafenib for three children with brainstem BRAF
Philippe L; Maria K; Tariq A; Sofia M; Christine SM; Jean-Pierre F; Dudley RW; Sébastien P; Nada J; Valérie L
J Neurooncol; 2019 Oct; 145(1):135-141. PubMed ID: 31502039
[TBL] [Abstract][Full Text] [Related]
7. Clinical response to dabrafenib plus trametinib in a pediatric ganglioglioma with
Miller KE; Schieffer KM; Grischow O; Rodriguez DP; Cottrell CE; Leonard JR; Finlay JL; Mardis ER
Cold Spring Harb Mol Case Stud; 2021 Apr; 7(2):. PubMed ID: 33637608
[TBL] [Abstract][Full Text] [Related]
8. Co-occurrence of histone H3 K27M and BRAF V600E mutations in paediatric midline grade I ganglioglioma.
Pagès M; Beccaria K; Boddaert N; Saffroy R; Besnard A; Castel D; Fina F; Barets D; Barret E; Lacroix L; Bielle F; Andreiuolo F; Tauziède-Espariat A; Figarella-Branger D; Puget S; Grill J; Chrétien F; Varlet P
Brain Pathol; 2018 Jan; 28(1):103-111. PubMed ID: 27984673
[TBL] [Abstract][Full Text] [Related]
9. The safety and efficacy of cobimetinib for the treatment of BRAF V600E or V600K melanoma.
Amaral T; Nouri N; Garbe C
Expert Rev Anticancer Ther; 2016 Jul; 16(7):705-15. PubMed ID: 27219630
[TBL] [Abstract][Full Text] [Related]
10. Vemurafenib in combination with cobimetinib in relapsed and refractory extramedullary multiple myeloma harboring the BRAF V600E mutation.
Mey UJM; Renner C; von Moos R
Hematol Oncol; 2017 Dec; 35(4):890-893. PubMed ID: 27641727
[TBL] [Abstract][Full Text] [Related]
11. The genetic landscape of ganglioglioma.
Pekmezci M; Villanueva-Meyer JE; Goode B; Van Ziffle J; Onodera C; Grenert JP; Bastian BC; Chamyan G; Maher OM; Khatib Z; Kleinschmidt-DeMasters BK; Samuel D; Mueller S; Banerjee A; Clarke JL; Cooney T; Torkildson J; Gupta N; Theodosopoulos P; Chang EF; Berger M; Bollen AW; Perry A; Tihan T; Solomon DA
Acta Neuropathol Commun; 2018 Jun; 6(1):47. PubMed ID: 29880043
[TBL] [Abstract][Full Text] [Related]
12. Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma.
Schindler G; Capper D; Meyer J; Janzarik W; Omran H; Herold-Mende C; Schmieder K; Wesseling P; Mawrin C; Hasselblatt M; Louis DN; Korshunov A; Pfister S; Hartmann C; Paulus W; Reifenberger G; von Deimling A
Acta Neuropathol; 2011 Mar; 121(3):397-405. PubMed ID: 21274720
[TBL] [Abstract][Full Text] [Related]
13. BRAF Inhibition in
Kaley T; Touat M; Subbiah V; Hollebecque A; Rodon J; Lockhart AC; Keedy V; Bielle F; Hofheinz RD; Joly F; Blay JY; Chau I; Puzanov I; Raje NS; Wolf J; DeAngelis LM; Makrutzki M; Riehl T; Pitcher B; Baselga J; Hyman DM
J Clin Oncol; 2018 Dec; 36(35):3477-3484. PubMed ID: 30351999
[TBL] [Abstract][Full Text] [Related]
14. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma.
Larkin J; Ascierto PA; Dréno B; Atkinson V; Liszkay G; Maio M; Mandalà M; Demidov L; Stroyakovskiy D; Thomas L; de la Cruz-Merino L; Dutriaux C; Garbe C; Sovak MA; Chang I; Choong N; Hack SP; McArthur GA; Ribas A
N Engl J Med; 2014 Nov; 371(20):1867-76. PubMed ID: 25265494
[TBL] [Abstract][Full Text] [Related]
15. Recurrent ganglioglioma in adults treated with BRAF inhibitors.
Chamberlain MC
CNS Oncol; 2016; 5(1):27-9. PubMed ID: 26680369
[TBL] [Abstract][Full Text] [Related]
16. Desmoplastic non-infantile astrocytoma/ganglioglioma: rare low-grade tumor with frequent BRAF V600E mutation.
Chatterjee D; Garg C; Singla N; Radotra BD
Hum Pathol; 2018 Oct; 80():186-191. PubMed ID: 29902580
[TBL] [Abstract][Full Text] [Related]
17. Mutant BRAF V600E protein in ganglioglioma is predominantly expressed by neuronal tumor cells.
Koelsche C; Wöhrer A; Jeibmann A; Schittenhelm J; Schindler G; Preusser M; Lasitschka F; von Deimling A; Capper D
Acta Neuropathol; 2013 Jun; 125(6):891-900. PubMed ID: 23435618
[TBL] [Abstract][Full Text] [Related]
18. Targeting CDK1 and MEK/ERK Overcomes Apoptotic Resistance in BRAF-Mutant Human Colorectal Cancer.
Zhang P; Kawakami H; Liu W; Zeng X; Strebhardt K; Tao K; Huang S; Sinicrope FA
Mol Cancer Res; 2018 Mar; 16(3):378-389. PubMed ID: 29233910
[TBL] [Abstract][Full Text] [Related]
19. Dabrafenib treatment in a patient with BRAF V600E ganglioglioma: circulating exosome-derived cancer RNA supports treatment choice and clinical monitoring.
Pasqualetti F; Restante G; Gonnelli A; Rofi E; Molinari A; Crucitta S; Paiar F; Rudà R; Danesi R; Soffietti R; Del Re M
Neuro Oncol; 2019 Dec; 21(12):1610-1611. PubMed ID: 31504796
[No Abstract] [Full Text] [Related]
20. Response of recurrent BRAFV600E mutated ganglioglioma to Vemurafenib as single agent.
del Bufalo F; Carai A; Figà-Talamanca L; Pettorini B; Mallucci C; Giangaspero F; Antonelli M; Badiali M; Moi L; Bianco G; Cacchione A; Locatelli F; Ferretti E; Mastronuzzi A
J Transl Med; 2014 Dec; 12():356. PubMed ID: 25524464
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]